Overview

Gender

male

Investor Type

Investment Partner

Scott Requadt, JD, MBA, is currently a Managing Director at Clarus Ventures, a life sciences venture capital fund. Scott has over 15 years of operating and investment experience in the pharmaceutical industry.

Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, and previously practiced for several years as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada.

Scott holds a B.Com (Economics & Finance) from McGill University, an LL.B from University of Toronto and an MBA from Harvard Business School (Baker Scholar).

Scott has been involved in multiple investments spanning both therapeutics and medtech, including Intercept Pharmaceuticals and several R&D risk-sharing collaborations with large pharma partners.

He has previously been active on the Boards of TyRx, Catabasis, Oxford Immunotec, VBI Vaccines, Link Medicine and Biolex Therapeutics.